September 7, 2018


PhaseBio Secures $34 Million in Series D Financing


“PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for orphan diseases, with an initial focus on cardiopulmonary disorders, today announced the completion of a $34 million Series D financing, including the conversion of existing convertible promissory notes.”

Proceeds from this financing will advance clinical development of PB2452, which is a potential first-in-class reversal agent for patients on ticagrelor, and PB1046, a novel treatment for PAH. PhaseBio, a clinical-stage biopharmaceutical company launched in 2006 from Duke innovators Drs. Ashutosh Chilkoti & Lori Setton are committed to developing new and improved biotherapeutics for the treatment of serious rare diseases, with an initial focus on cardiopulmonary indications.


For more information and to read the full story, click here


[Originally posted by PhaseBio — September 5, 2018]